Arrowhead Research Up Over 6% Following CNBC Comments

Shares of Arrowhead Research ARWR are trending higher following bullish comments from CNBC’s Fast Money.

“Upside 100 to 200 percent- downside 20 percent,” said Robyn Karnauskas, Deutsche Bank biotechnology director.

Arrowhead is currently developing a drug to treat hepatitis B and is expected to release data on its progress in the third quarter.

Karnauskas also commented that Arrowhead is a likely takeout target. This is often the case for small pharmaceutical companies who are not partnered with a giant in the space to help with trials and commercialization.

Shares of Arrowhead are up nearly seven percent Wednesday to $12.15.